L
Lars Christian Rump
Researcher at University of Düsseldorf
Publications - 248
Citations - 12878
Lars Christian Rump is an academic researcher from University of Düsseldorf. The author has contributed to research in topics: Blood pressure & Kidney. The author has an hindex of 51, co-authored 229 publications receiving 11322 citations. Previous affiliations of Lars Christian Rump include Ruhr University Bochum.
Papers
More filters
Journal ArticleDOI
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): A randomised controlled trial
Murray D. Esler,Henry Krum,Paul A. Sobotka,Markus P. Schlaich,Roland E. Schmieder,Michael Böhm,Felix Mahfoud,Horst Sievert,Nina Wunderlich,Lars Christian Rump,Oliver Vonend,Michael Uder,Mel Lobo,Mark J. Caulfield,Andrejs Erglis,Michel Azizi,Marc Sapoval,S. Thambar,Alexandre Persu,Jean Renkin,Heribert Schunkert,Joachim Weil,Uta C. Hoppe,Tony Walton,Dierk Scheinert,Thomas Binder,Andrzej Januszewicz,Adam Witkowski,Luis M. Ruilope,Robert Whitbourn,Heike Bruck,Mark Downes,Thomas F. Lüscher,Alan G. Jardine,Mark Webster,Thomas Zeller,Jerzy Sadowski,Krzysztof Bartus,Craig A. Straley,Neil C. Barman,David P. Lee,Ronald M. Witteles,Vivek Bhalla,Joseph M. Massaro +43 more
TL;DR: Catheter-based renal denervation can safely be used to substantially reduce blood pressure in treatment-resistant hypertensive patients and should be continued, according to the authors.
Journal ArticleDOI
Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes
Hermann Haller,Sadayoshi Ito,Joseph L. Izzo,Andrzej Januszewicz,Shigehiro Katayama,Jan Menne,Albert Mimran,Ton J. Rabelink,Eberhard Ritz,Luis M. Ruilope,Lars Christian Rump,Giancarlo Viberti +11 more
TL;DR: Olmesartan was associated with a delayed onset of microalbuminuria, even though blood-pressure control in both groups was excellent according to current standards.
Journal ArticleDOI
Short-Chain Fatty Acid Propionate Protects From Hypertensive Cardiovascular Damage
Hendrik Bartolomaeus,András Balogh,Mina Yakoub,Susanne Homann,Lajos Markó,Sascha Höges,D. Tsvetkov,D. Tsvetkov,D. Tsvetkov,Alexander Krannich,Sebastian Wundersitz,Sebastian Wundersitz,Ellen G. Avery,Nadine Haase,Kristin Kräker,Lydia Hering,Martina Maase,Kristina Kusche-Vihrog,Maria Grandoch,Jens Fielitz,Stefan Kempa,Maik Gollasch,Maik Gollasch,Zhaxybay Zhumadilov,Samat Kozhakhmetov,Almagul Kushugulova,Kai-Uwe Eckardt,Ralf Dechend,Lars Christian Rump,Sofia K. Forslund,Dominik N. Müller,Johannes Stegbauer,Nicola Wilck +32 more
TL;DR: The data suggest that lifestyle modifications leading to augmented SCFA production could be a beneficial nonpharmacological preventive strategy for patients with hypertensive cardiovascular disease and emphasize an immune-modulatory role of SCFAs and their importance for cardiovascular health.
Journal ArticleDOI
Renal Hemodynamics and Renal Function After Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension
Felix Mahfoud,Bodo Cremers,Julia Janker,Britta Link,Oliver Vonend,Christian Ukena,Dominik Linz,Roland E. Schmieder,Lars Christian Rump,Ingrid Kindermann,Paul A. Sobotka,Henry Krum,Bruno Scheller,Markus P. Schlaich,Ulrich Laufs,Michael Böhm +15 more
TL;DR: RD reduced blood pressure, renal resistive index, and incidence of albuminuria without adversely affecting glomerular filtration rate or renal artery structure within 6 months and appears to be a safe and effective therapeutic approach to lower blood pressure in patients with resistant hypertension.
Journal ArticleDOI
Ambulatory Blood Pressure Changes After Renal Sympathetic Denervation in Patients With Resistant Hypertension
Felix Mahfoud,Christian Ukena,Roland E. Schmieder,Bodo Cremers,Lars Christian Rump,Oliver Vonend,Joachim Weil,Martin Schmidt,Uta C. Hoppe,Thomas Zeller,Axel Bauer,Christian Ott,Erwin Blessing,Paul A. Sobotka,Henry Krum,Markus P. Schlaich,Murray D. Esler,Michael Böhm +17 more
TL;DR: RDN reduced office BP and improved relevant aspects of ambulatory BP monitoring, commonly linked to high cardiovascular risk, in patients with true-treatment resistant hypertension, whereas it only affected office BP in pseudoresistant hypertension.